Letolizumab

Drug Profile

Letolizumab

Alternative Names: BMS-986004; BMS2h-572-633-CT-L2

Latest Information Update: 28 Jan 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Immune thrombocytopenic purpura

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2014 Phase-I/II clinical trials in Immune thrombocytopenic purpura in USA (IV)
  • 28 Oct 2014 Bristol-Myers Squibb plans a phase I/II trial in Immune Thrombocytopenic Purpura in USA (NCT02273960)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top